Japanese drug maker Kyorin Pharmaceutical signed a licensing agreement with Eisai Sept. 29 giving Eisai exclusive rights to develop and market overactive bladder agent Uritos (imidafenacin) in China, India, Sri Lanka and 10 ASEAN countries
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.
